Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jul 18 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

This antifungal treatment is intended for the topical management of toenail infections caused by specific fungi. The drug will be produced at the company's manufacturing facility in Ahmedabad, India. The press release highlights that the approved product had significant annual sales in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases